Antibodies and other biomarkers – pathological consequences (2)

1 Alves JD Grima B . Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 2003; 5: 383 – 390 .

2 Delgado Alves J Kumar S Isenberg DA . Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2003; 42: 893 – 899 .

3 Martin F Chan AC . B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467 – 496 .

4 Jacobi AM Odendahl M Reiter K . Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1332 – 1342 .

5 Mauri C Gray D Mushtaq N Londei M . Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003; 197: 489 – 501 .

6 Evans JG Chavez-Rueda KA Eddaoudi A . Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007; 178: 7868 – 7878 .

7 Aitman TJ Dong R Vyse TJ . Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439: 851 – 855 .

8 Fanciulli M Norsworthy PJ Petretto P . FCGR3B copy number variation is associated with susceptibility to systemic but not organ-specific autoimmunity. Nat Genet 2007; 39: 721 – 723 .